For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis
The selective 5-hydroxytryptamine3 ( 5HT3 ) antagonist ondansetron has been shown to be an effective antiemetic in patients receiving cisplatin chemotherapy . This double-blind study compared the efficacy and safety of three doses of intravenous ondansetron in the prevention of nausea and vomiting associated with high-dose ( ≥100 mg/m2 ) cisplatin chemotherapy . A total of 125 patients were r and omized ( 1∶1∶1 ) to receive 0.015 , 0.15 , or 0.30 mg/kg every 4 h for a total of 3 doses . All patients were monitored for emetic episodes , adverse events , and laboratory safety parameters for 24 h following cisplatin administration . The 0.15-mg/kg dose was superior to the 0.015-mg/kg dose with respect to the median number of emetic episodes ( P=0.033 ) and complete response ( no emetic episodes , P=0.005 ) . No statistically significant difference was found between the 0.15 and the 0.30-mg/kg groups . The most common adverse event was headache . Three 0.15-mg/kg doses of intravenous ondansetron are safe , effective , and adequate for the control of cisplatin-induced emesis
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .